Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to non-linear pharmacokinetics.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40% bound, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg (mean 0.45 L/kg). Higher Vd in neonates (0.6–0.9 L/kg) and patients with cirrhosis. Vd approximates total body water; distribution is rapid into well-perfused tissues, less into adipose tissue.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96%–100% (almost complete). Oral sustained-release: 80%–100% (variable due to formulation-dependent release; food may increase rate but not extent for some products). Rectal: variable, approximately 80–90% (solution/suppository dependent).
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No dose adjustment required for GFR > 10 m L/min; for GFR < 10 m L/min, reduce dose by 50% and monitor serum levels
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use or use with extreme caution and monitor levels
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Initial 5 mg/kg/day in divided doses every 6-8 hours, titrate based on serum levels; typical maintenance: 1-12 years: 20 mg/kg/day (max 800 mg/day), >12 years: 16 mg/kg/day (max 900 mg/day)
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing range (e.g., 300 mg/day extended-release) with frequent monitoring due to decreased clearance; avoid doses exceeding 400 mg/day without serum level guidance
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning for theophylline.
None.
Narrow therapeutic index; monitor serum levels. Risk of cardiac arrhythmias and seizures, especially at high levels. Use with caution in patients with cardiac disease, hepatic impairment, or those receiving other methylxanthines.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation. Concurrent use of other methylxanthines.
Hypersensitivity to theophylline or any component of the formulation.
High-carbohydrate, low-protein diets can increase theophylline toxicity by reducing clearance. Charcoal-broiled meats and cruciferous vegetables (broccoli, Brussels sprouts, kale) may increase metabolism, potentially reducing efficacy. Avoid large amounts of caffeine-containing products (coffee, tea, cola, energy drinks) as they can exacerbate CNS and cardiac adverse effects.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No known teratogenic effects; however, neonatal withdrawal (irritability, jitteriness, apnea) may occur with third-trimester exposure. High maternal levels may be associated with fetal tachycardia and intrauterine growth restriction.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7. Infant exposure is estimated at 1-10% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability or jitteriness. The American Academy of Pediatrics considers it compatible with breastfeeding, but risk-benefit assessment should be individualized.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Theophylline clearance decreases in the third trimester, leading to prolonged half-life. Dose reduction of 20-30% may be required to avoid toxicity. Monitor serum levels frequently (at least every 2-4 weeks) and adjust dose to maintain therapeutic concentrations. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring upward dose adjustment.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels closely, especially when interacting drugs (e.g., cimetidine, fluoroquinolones, macrolides) are added or removed. Use with caution in patients with hepatic impairment, heart failure, or COPD exacerbation as clearance decreases. Cigarette smoking induces metabolism, requiring dose adjustments. Slow IV infusion over 20-30 minutes to avoid hypotension and arrhythmias.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose or stop without consulting your doctor.,Avoid smoking or use of nicotine products as they alter theophylline levels.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Store medication at room temperature away from moisture and heat.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
"Theophylline, a cytochrome P450 (CYP) 1A2 substrate and inhibitor, may reduce the metabolic clearance of lobeglitazone, which is primarily metabolized by CYP1A2. This can lead to increased plasma concentrations of lobeglitazone, potentially enhancing its therapeutic effects and risk of adverse events such as peripheral edema, weight gain, and hypoglycemia. Clinically, patients receiving both drugs should be monitored for signs of lobeglitazone toxicity, and dose adjustments may be necessary."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, inhibits CYP1A2 isoenzyme activity, which is the primary metabolic pathway for theophylline. Concomitant administration can lead to a significant increase in theophylline serum concentrations, elevating the risk of theophylline toxicity, including nausea, vomiting, cardiac arrhythmias, and seizures. Clinical monitoring and dose adjustment of theophylline are necessary to avoid adverse effects."
"Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may decrease the metabolic clearance of theophylline, a xanthine derivative bronchodilator, through competitive inhibition of cytochrome P450 (CYP) 1A2 enzymes. This interaction can lead to elevated serum theophylline concentrations, increasing the risk of theophylline toxicity, which may manifest as nausea, vomiting, arrhythmias, or seizures. Clinical monitoring and dose adjustment of theophylline are warranted to prevent adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL vs AEROLATE JR, answered by our medical review team.
THEOPHYL is a Bronchodilator that works by Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL is: 300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL is classified as Category C. Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No . AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.